ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
ACE2 | Angiotensin I converting enzyme 2 | Enzymes FDA approved drug targets Predicted membrane proteins
| | | | | Tissue enhanced |
ACY3 | Aspartoacylase (aminocyclase) 3 | Enzymes
| | | | | Tissue enhanced |
AGR2 | Anterior gradient 2 | Predicted secreted proteins
| | | | | Tissue enhanced |
AGR3 | Anterior gradient 3 | Predicted secreted proteins
| | | | | Tissue enhanced |
AKR1B10 | Aldo-keto reductase family 1, member B10 (aldose reductase) | | | | | | Tissue enhanced |
AKR1B15 | Aldo-keto reductase family 1, member B15 | | | | | | Tissue enhanced |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ANXA13 | Annexin A13 | Plasma proteins
| | | | | Tissue enhanced |
ARHGDIG | Rho GDP dissociation inhibitor (GDI) gamma | | | | | | Tissue enhanced |
B3GALT5 | UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 | Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT3 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
B3GNT7 | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | Predicted secreted proteins
| | | | | Tissue enhanced |
B4GALNT2 | Beta-1,4-N-acetyl-galactosaminyl transferase 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
B4GALNT3 | Beta-1,4-N-acetyl-galactosaminyl transferase 3 | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
BCAS1 | Breast carcinoma amplified sequence 1 | | | | | | Tissue enhanced |
BPIFB1 | BPI fold containing family B, member 1 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
C15orf48 | Chromosome 15 open reading frame 48 | | | | | | Tissue enhanced |
C1orf106 | Chromosome 1 open reading frame 106 | | | | | | Tissue enhanced |
CA2 | Carbonic anhydrase II | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enhanced |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CACNA1A | Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit | Disease related genes FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
CAPN9 | Calpain 9 | Enzymes
| | | | | Tissue enhanced |
CDHR5 | Cadherin-related family member 5 | Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CEACAM1 | Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) | CD markers Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
CLDN3 | Claudin 3 | Cancer-related genes Disease related genes Predicted membrane proteins
| | | | | Tissue enhanced |
CYP4F12 | Cytochrome P450, family 4, subfamily F, polypeptide 12 | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
DAB1 | Dab, reelin signal transducer, homolog 1 (Drosophila) | | | | | | Tissue enhanced |
DDC | Dopa decarboxylase (aromatic L-amino acid decarboxylase) | Disease related genes Enzymes FDA approved drug targets
| | | | | Tissue enhanced |
DPEP1 | Dipeptidase 1 (renal) | Enzymes FDA approved drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
DPP4 | Dipeptidyl-peptidase 4 | CD markers Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EPCAM | Epithelial cell adhesion molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
EXOC3L4 | Exocyst complex component 3-like 4 | | | | | | Tissue enhanced |
FAM211A | Family with sequence similarity 211, member A | | | | | | Tissue enhanced |
FOLH1 | Folate hydrolase (prostate-specific membrane antigen) 1 | Cancer-related genes Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
FOXA2 | Forkhead box A2 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
FOXQ1 | Forkhead box Q1 | Cancer-related genes Transcription factors
| | | | | Tissue enhanced |
GALNT5 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5) | Enzymes
| | | | | Tissue enhanced |
GALNT6 | UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (GalNAc-T6) | Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |
GCNT3 | Glucosaminyl (N-acetyl) transferase 3, mucin type | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
GDA | Guanine deaminase | Enzymes Plasma proteins
| | | | | Tissue enhanced |
GNG13 | Guanine nucleotide binding protein (G protein), gamma 13 | RAS pathway related proteins
| | | | | Tissue enhanced |
HIST1H2BH | Histone cluster 1, H2bh | | | | | | Tissue enhanced |
HNF1A | HNF1 homeobox A | Cancer-related genes Disease related genes Transcription factors
| | | | | Tissue enhanced |
HNF4A | Hepatocyte nuclear factor 4, alpha | Disease related genes Nuclear receptors Transcription factors
| | | | | Tissue enhanced |
HOXD12 | Homeobox D12 | Transcription factors
| | | | | Tissue enhanced |
HRASLS2 | HRAS-like suppressor 2 | Predicted membrane proteins
| | | | | Tissue enhanced |
IL17REL | Interleukin 17 receptor E-like | | | | | | Tissue enhanced |
KLK15 | Kallikrein-related peptidase 15 | Cancer-related genes Enzymes Predicted secreted proteins
| | | | | Tissue enhanced |